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Abstract
Asthma is a chronic disease that affect millions of persons around the
world and it has gained an increasing concern in the world health orga-
nizations. To fight this disease there are some options, the short acting
β-2 agonist salbutamol, or the inhaled corticosteroids, like beclomethasone
dipropionate, budesonide, ciclesonide and fluticasone propionate.
Cyclodextrins are a family of oligosaccharides containing several d-glucopy-
ranose units linked by α(1-4) glycosidic bonds. The three most common
used, α-, β- and γ-cyclodextrins, and some of their derivatives are widely
used in the pharmaceutical industry as excipients with the main purpose
of complexing with the anti-asthmatic drugs and increase their aqueous
solubility, stability and bioavailability.
In this work, using molecular docking and quantum mechanics calculations,
it was possible to identify the preferential binding modes and calculate
their energies of binding. The space inside the cyclodextrins’ cavities is
important for the accommodation of guest molecules, influencing the de-
gree of inclusion. α- and γ-cyclodextrins are not very good hosts because
their cavity spaces are too small or too large, respectively. On the other
hand, β-cyclodextrin and its derivatives (methyl- and 2-hydroxypropyl-
cyclodextrins) exhibited very good size complementary with the drugs stud-
ied. 2-hydroxypropyl-β-cyclodextrin appeared to be particularly good form-
ing stable adducts with most drugs. This cyclodextrin seems to conjugate
the correct cavity size, with increased hydrophobicity and extra hydroxyl
groups for non-specific and specific interactions with the guests, respec-
i
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tively.
In overall, our computational approach was able to correctly predict qual-
itatively the best matches between the anti-asthmatic drugs and the cy-
clodextrins. An example is the adduct formed between salbutamol and
2-hydroxypropyl-β-cyclodextrin, with no stability values measured experi-
mentally, which we expect to be very strong. This remarkable predictive
ability shows that our computational method can be a powerful tool de-
signing new and unexplored combinations of adducts.
Keywords: asthma, adducts, free energy, molecular docking, quan-
tum mechanics
Resumo
A asma e´ uma doenc¸a cro´nica que afeta milho˜es de pessoas em todo o
mundo e tem vindo a aumentar o seu nu´mero de casos nas u´ltimas de´cadas.
Atualmente a Organizac¸a˜o Mundial de Sau´de considera-a uma das prin-
cipais doenc¸as. O combate a` asma iniciou-se em 1960 com a descoberta
dos recetores adrene´rgicos e subsequente, o recetor β. Com esta descoberta
desenvolveram-se os agonistas β-2 de ac¸a˜o curta como o salbutamol, espec´ı-
ficos para o recetor β-2, mais tarde na de´cada de 80 surgiram os agonistas
β-2 de ac¸a˜o prolongada. Foi no in´ıcio da de´cada seguinte que se descobri-
ram os corticostero´ides, como a beclometasona dipropionato, budesonida,
ciclesonida e fluticasona propionato, muito importantes no tratamento de
casos mais severos de asma.
As ciclodextrinas sa˜o oligossaca´ridos c´ıclicos, constitu´ıdos por va´rias unida-
des de d-glucopiranose conectadas atrave´s de uma ligac¸a˜o glicos´ıdica α(1-
4). Atualmente existem treˆs ciclodextrinas principais, que sa˜o: a α, a β e a
γ. A descoberta das ciclodextrinas remonta ao final do se´culo XIX quando
foram extra´ıdas pela primeira vez. Desde enta˜o muitos grupos de inves-
tigac¸a˜o dedicaram-se a` s´ıntese e caraterizac¸a˜o destes compostos. As suas
propriedades f´ısico-qu´ımicas foram o que levaram ao desenvolvimento dos
seus derivados de modo a melhorar as propriedades das anteriores. Nos dias
de hoje teˆm uma ampla aplicac¸a˜o, desde a indu´stria alimentar, a` cosme´tica e
farmaceˆutica. A sua importaˆncia ao n´ıvel da indu´stria farmaceˆutica prende-
se com o facto das ciclodextrinas melhorarem a solubilidade, estabilidade e
biodisponilidade dos fa´rmacos.
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Para estudar os modos de ligac¸a˜o e energias livres dos complexos forma-
dos entre ciclodextrinas e fa´rmacos, foram selecionadas cinco ciclodextri-
nas, as treˆs mais comuns, α, β e γ-ciclodextrinas, e duas derivadas da
β-ciclodextrina, a metil- e 2-hidroxipropil-β-ciclodextrinas. Os fa´rmacos
seleccionados foram o salbutamol, agonista β-2 de ac¸a˜o curta, atualmente
o mais utilizado no mercado e quatro corticostero´ides de resposta prolon-
gada, a beclometasona dipropionato, budesonida, fluticasona propionato e
o pro-fa´rmaco ciclesonida.
Inicialmente, neste estudo, otimizaram-se as estruturas das mole´culas com
o programa Avogadro, usando o me´todo de “steepest descent” e o campo de
forc¸a MMFF94. De seguida, as otimizac¸o˜es de geometria foram realizadas
ao n´ıvel quaˆntico com o Gaussian 09, com funcional PBE1PBE e a basis
set 6-31G(d,p). Todos os ca´lculos foram realizados em va´cuo com carga
zero e multiplicidade um. Foram tambe´m calculadas as frequeˆncias destes
compostos de modo a garantir que a estrutura otimizada e´ um mı´nimo
de energia. Apo´s estes ca´lculos iniciais, deu-se in´ıcio a um estudo de do-
cking molecular. Recorrendo ao programa AutoDockTools foram prepara-
dos os ficheiros de iniciac¸a˜o com a remoc¸a˜o dos a´tomos na˜o polares em
todas as estruturas e introduc¸a˜o de flexibilidade nos fa´rmacos. De seguida
foi preparada uma grelha centrada no recetor, neste estudo sa˜o as ciclodex-
trinas, com largura suficiente na regia˜o superior e inferior de modo a serem
explorados os modos de ligac¸a˜o com o programa AutoDock Vina. De cada
estudo resultaram aproximadamente mil soluc¸o˜es que de seguida sofreram
um processo de permutac¸a˜o, devido a` elevada simetria dos recetores, que
podiam dar a ilusa˜o de termos soluc¸o˜es muito diferentes quando na real-
idade apenas esta˜o em subunidades diferentes. Estas estruturas tambe´m
foram agrupadas em clusters de modo a facilitar o estudo dos modos de
ligac¸a˜o preferenciais. A partir do docking molecular va´rios modos de lig-
ac¸a˜o foram selecionados. O crite´rio para selec¸a˜o destes modos de ligac¸a˜o
foram: o tamanho do cluster, isto e´, o nu´mero de soluc¸o˜es que o compo˜em,
e as energias do docking. Para cada cluster selecionado apenas e´ estu-
dada a estrutura com a menor energia. Entramos agora na u`ltima fase do
vnosso estudo, com a selec¸a˜o de dois a quatro modos de ligac¸a˜o para cada
complexo. Procedemos mais uma vez ao ca´lculo das estruturas otimizadas
usando mecaˆnica quaˆntica e paraˆmetros iguais aos utilizados no in´ıcio deste
estudo. O objetivo passou por obter a estrutura otimizada de cada modo
de ligac¸a˜o, mas tambe´m garantir que a estrutura e´ um mı´nimo de ener-
gia, bem como calcular as respetivas energias livres atrave´s de ca´lculos de
frequeˆncias.
A partir dos resultados de docking molecular e posterior otimizac¸a˜o de ge-
ometria e´ poss´ıvel dizer que a α-ciclodextrina, para estes casos, na˜o aparenta
ser um bom composto de inclusa˜o na medida que apenas introduz na sua
cavidade uma cadeia lateral dos fa´rmacos maiores e mesmo no caso do
fa´rmaco mais pequeno a estrutura mais esta´vel e´ a de na˜o inclusa˜o. No
caso da β-ciclodextrina existe uma maior variedade de modos de ligac¸a˜o
e um aumento no n´ıvel de inclusa˜o dos fa´rmacos. A metil-β-ciclodextrina
com a substituic¸a˜o do a´tomo de hidroge´nio por um grupo metilo na regia˜o
mais larga das ciclodextrina onde existiam dois grupos hidroxilo por sub-
unidade, verificou-se uma dificuldade por parte dos fa´rmacos em interagir
neste lado, levando assim a uma diminuic¸a˜o na propriedade deste recetor
em atuar como doador de ligac¸o˜es de hidroge´nio. Neste caso, o aumento da
hidrofobicidade que podendo ter um papel importante na afinidade, veio
diminuir a especifidade do recetor para estes ligandos. No caso da 2-
hidroxipropil-β-ciclodextrina, com a substituic¸a˜o do a´tomo de hidroge´nio
no grupo hidroxilo prima´rio na zona mais estreita da ciclodextrina por
um grupo 2-hidroxipropilo, observamos um aumento da hidrofobicidade da
cavidade enquanto tambe´m aumentou a possibilidade de criar ligac¸o˜es de
hidroge´nio com o grupo adicionado. Com esta alterac¸a˜o o n´ıvel de inserc¸a˜o
dos fa´rmacos, principalmente dos corticostero´ides aumentou, provavelmente
devido a uma melhorar acomodac¸a˜o no interior da cavidade, mas tambe´m
devido a` possibilidade de criac¸a˜o de ligac¸o˜es de hidroge´nio em ambos os
lados das ciclodextrina.
No que toca a`s energias de ligac¸a˜o, grande parte ainda se encontra a calcular,
a` excec¸a˜o dos complexos com o salbutamol. Os resultados esta˜o de acordo
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com os obtidos no docking molecular, sendo que a α- e γ-ciclodextrinas
obtiveram os piores valores devido a`s suas cavidades serem demasiado pe-
quenas ou grandes, respetivamente. As baixas energias de ligac¸a˜o para a
β- e metil-β-ciclodextrinas esta˜o em excelente concordaˆncia com os maiores
valores da constante de estabilidade medidos experimentalmente. Curiosa-
mente, os nossos dados computacionais indicam que o salbutamol teria uma
constante de solubilidade maior caso a 2-hidroxipropil-β-ciclodextrina fosse
utilizada como recetor.
Em conclusa˜o, a nossa abordagem computacional foi capaz de prever quali-
tativamente as melhores complementaridades entre os fa´macos anti-asma´ti-
cos e as ciclodextrinas. Esperamos que as energias livres de ligac¸a˜o de Gibbs,
quando terminadas, corroborem o que ja´ foi observado. Um exemplo, e´ o
complexo formado entre o salbutamol e a 2-hidroxipropilo-β-ciclodextrina,
cuja constante de estabilidade na˜o foi estudada experimentalmente, mas
esperamos que seja elevada.
Esta nota´vel capacidade preditiva mostra que o nosso me´todo computa-
cional pode ser uma ferramenta poderosa na concec¸a˜o de novas e inexplo-
radas combinac¸o˜es de complexos.
Palavras-chave: asma, complexos, energia livre, docking molecu-
lar, mecaˆnica quaˆntica
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Chapter 1
Introduction
1.1 Asthma
Asthma is a chronic disease whose history is characterized by recurring
episodes of lack of air. Its definition contains four components: symptoms
and variable airflow obstruction (bronchoconstriction), easily assessed by
clinicians; airway inflammation and airway hyper-responsiveness, that are
less accessible to the clinical practice and characterise the subjacent dis-
ease. Despite all this four domains being usually present, the diagnose of
asthma is mainly based on the symptoms associated with the narrowing
of small airways and possibly include shortness of breath, wheezing, chest
tightness and cough. However this symptoms are not specific and exclusive
to this disease and can be found in other respiratory conditions like, chronic
obstructive pulmonary disease and even in nonrespiratory diseases such as
obesity and cardiac failure [1, 2].
Asthma is a disease recognized since the ancient times [3], nowadays is con-
sidered an inflammatory disorder with an high level of prevalence, affecting
300 million people worldwide and is expected to affect 100 million more
until 2025 [4]. In addiction to its effect on people, asthma is also associated
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with an enormous economic burden on health care systems and society. [5].
The Global Initiate for Asthma (GINA) guidelines provided a schema to
classify asthma severity into four steps, regarding the clinical features of
patients before treatment and the response to the treatment according to
the daily medication [6]. Despite all the advances in understanding this
disease and a growing acceptance of these guidelines, an inadequate control
of asthma is still common, with nefarious consequences to various aspects
of daily life, including sleep, work, study and exercise [4].
1.2 Anti-asthmatic drugs
For centuries, strong coffee and tea were recommended for the relief of
asthma, then in the beginning of the 20th century epinephrine (or adrenaline),
became the standard bronchodilator used for the treatment of asthma. But
in the 60s decade, a breakthrough happened with the discovery of the adren-
ergic receptors, divided into the α and β receptors, with a subdivision into
the β-1, located in the heart and intestinal smooth muscle, and the β-2
on the bronchial and uterus smooth muscle. With this discovery, the β-
agonists emerged, first was isoprenaline and, later on, salbutamol (SAL)
(Figure 1.1e) was developed as a selective β-2 agonist; becoming nowa-
days the most used short acting β-2 agonist in the treatment of asthma.
The last step in this discovery series came in the 1980s with the develop-
ment of the long acting β-2 agonists, like salmeterol and formoterol, with
fast acting mechanisms and prolonged effects (> 12 hours) [3].
During the next decade a new type of drugs, that were already in devel-
opment but not yet in the market due to some side effects and its poor
lung selectivity by the inhaled route, reached a turning point with the dis-
covery of beclomethasone dipropionate (BDP), an inhaled corticosteroid.
Since then, others corticosteroids were developed, like fluticasone propi-
onate (FP), budesonide (BUD), and a few years ago in 2008, ciclesonide
(CIC), a pro-drug that is transformed in its active form by the esterases in
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the lungs (Figures 1.1a-d) [1].
Presently, these two approaches for the treatment of asthma are the most
used, individually or combined, depending on the severity of the asthma
case. However, there are other treatments like anti-leukotrienes and anti-
immunoglobulin E.
(a) Beclomethasone dipropi-
onate (BDP)
(b) Budesonide (BUD) (c) Ciclesonide (CIC)
(d) Fluticasone propionate
(FP)
(e) Salbutamol (SAL)
Figure 1.1: Schematic structure of the anti-asthmatic drugs used
in this study.
1.3 Cyclodextrins
The cyclodextrins (CyDs) are cyclic oligosaccharides of several d-glucopyra-
nose units linked by α(1-4) glycosidic bonds. There are 3 native and most
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commonly used CyDs: α-cyclodextrin (α-CyD), β-cyclodextrin (β-CyD)
and γ-cyclodextrin (γ-CyD), consisting of six, seven and eight units, re-
spectively [7].
(a) α-CyD (b) β-CyD (c) γ-CyD
Figure 1.2: Schematic structures of α-, β- and γ-cyclodextrins.
Image adapted from [8] .
1.3.1 A scope through history
The first reference of a substance that later was shown to be a CyD oc-
curred in 1891 [9]. Villiers, a french scientist obtained a small amount
of a crystalline product, that he called “cellulosine”, by digesting starch,
one of the most abundant carbohydrates in nature as cellulose and sucrose,
with Bacillus amylobacter. Many scientists later on, defended that he used
impure cultures and the cyclodextrins were indeed produced by another
bacteria, Bacillus macerans. This bacteria provided the cyclodextrin gly-
cosyl transferase (CGTase, EC 2.4.1.19) the enzyme responsible for the
production of the cyclic dextrin or cyclodextrin, which included the most
common ones, but also some large cyclodextrins with more than nine units
of glucopyranose [10–12].
During the 20th, century there were many research groups involved in the
production of cyclodextrins. Many authors divide this century in three
major stages of development for the CyDs technology [9]:
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• The discovery period - It started with Villiers’ discovery and ended
in the late 30s. It was a time marked by the findings of Franz
Schardinger, an Austrian microbiologist, that isolated two different
dextrins which he called α- and β-dextrin using the starch and the
microorganism Bacillus macerans, and for the elucidation of the cyclic
structure of these two dextrins, by Freudenberg and his coworkers in
the second half of 1930s [13].
• The exploration period - From 1936 until 1970, it was a time of high
level research and discovery. Between 1948-50 γ-CyD was discovered
and its structure was elucidated. In the beginning of 1950, French and
Cramer groups began to work on the enzymatic production of CyDs
with the main goal to isolate them with high level of purity and char-
acterise their real physicochemical properties. Cramer and coworkers
obtained in 1953 the first patent regarding this subject covering the
most important aspects of the CyDs applications. The first review
was published by French in 1957 along with the first misinformation
concerning the toxicity of cyclodextrins. Until this date not much
had been published about toxicological studies of CyDs, discouraging
many scientists to develop products containing CyDs for two and half
decades. By the end of 1960s, the methods to prepare cyclodextrins
on a laboratory scale, their structure and physicochemical properties
were elucidated [9, 11, 13].
• The industrial period - Many industries got involved in the production
of CyDs and a product that a while ago costed two thousand dollars
per kilogram, and was only available as a rare chemical, started to be
produced by half a dozen of industries worldwide and the price lowered
to near five dollars. Not only the quantity produced increased but
also its quality during production, due to improvements in the genetic
engineering with the design of different types of CGTases, more active
and specific than the previous ones [9, 11, 13].
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1.3.2 Physicochemical properties
The most important structural feature that is evidenced from the three-
dimensional structures of CyDs is their torus shape with secondary hydroxyl
groups located in the wider edge of the ring, whereas the primary hydroxyl
groups are in the narrow edge. This structure provides the CyD an hy-
drophilic outside with the ability of dissolve in water and an hydrophobic
cavity allowing them to form stable complexes with guest molecules [9, 10].
In the next table (Table 1.1) there are presented some physicochemical
properties of the most common cyclodextrins and two derivatives of β-CyD,
methyl-β- (Me-β-) and 2-hydroxypropyl-β-CyD (Hp-β-CyD).
Table 1.1: Properties of the cyclodextrins used in this work.
Properties
Cyclodextrins
α β Me-β Hp-β γ
no. of subunits 6 7 8
formula C36H60O30 C42H70O35 C49H84O35 C63H112O42 C48H80O40
MW, Da 972.85 1134.99 1312 1400 1297.14
cavity diam., A˚ 4.7-5.3 6.0-6.5 7.5-8.3
solubility
a
145 18.5 >500 >600 232
a Solubility in pure water at about 25oC (mg·ml−1)[11].
The surrounding water molecules can have an important role in the aggre-
gation process of cyclodextrins, which results in the different solubilities
observed. In fact, an odd number of subunits enhances the probability of
making intramolecular hydrogen bonds, increasing aggregation and lower-
ing solubility [7]. The structural modifications of the parental cyclodextrins
led to new derivatives with improved properties and new applications.
The driving forces leading to the inclusion properties of CyDs include:
dipole-dipole electrostatic interactions; the van der Waals interactions, in
specific, the dipole-induced dipole interactions and the London dispersion
forces; hydrophobic interactions; and hydrogen bonding [14].
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1.3.3 Drug delivery systems
Drugs require good water solubility and, at the same time, lipophilicity
enough to cross the membrane. Therefore one of the most important prop-
erties, for cyclodextrins to be considered an excellent carrier, is their solubil-
ity. CyDs have the ability to incorporate drugs and increase their delivery
in the biological membranes, increasing the availability near the membrane
and in the bloodstream [15].
Another important aspect of the encapsulation is the improved stability
of the drugs, making them less vulnerable to degradation due to chemi-
cal reactions, heat or light. This inclusion is also important when dealing
with drugs that cause irritation, for instance, of the gastric mucosa when
administrated orally [10].
CyDs are mostly biologically inactive, since they are poorly absorbed in the
membrane, probably due to the bulky shape and hydrophilic nature. Their
lack of toxicity are also relevant for industries that want to use cyclodextrins
as excipients in the formulation of drugs [15].
1.3.4 Cyclodextrins adducts with anti-asthmatic
drugs
There are already experimental data measured for the association between
these cyclodextrins and anti-asthmatic drugs. In Table 1.2 are presented
the stability constants (Ks) available in the literature. Ks measures the
strength of the interaction between two molecules (guest and host) that
come together to form the adduct. Higher values of the constant corre-
sponds to more stable adducts. The SAL drug forms very stable complexes
with β-CyD and its derivative, Me-β. BDP clearly prefers the Hp-β-CyD,
while BUD and FP have their higher stability when complexed with the
larger γ-CyD. CIC forms a very stable adduct with Me-β-CyD. The general
trend from the data in Table 1.2 is that these drugs prefer to interact with
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larger CyDs, and in some cases, also prefer some derivatives instead of the
unmodified CyDs.
Table 1.2: Stability constants values (M−1) for the available
adducts at different temperatures.
Drugs Temperature / oC
CyDs
Reference
α β Me-β Hp-β γ
BDP 25 226.7 22.6 681.6 [16]
BUD - 1195 4578 [17]
CIC
25 14880 [18]
- 743.7 149.7 [19]
FP - 192.9 3093.7 [20]
SAL
37 1.3 68.9 82.7 5.2
25 1.1 69.3 61.9 5.1
20 1.1 66.4 78.7 5.1
[21]
1.4 Quantum and Molecular Mechanics
At the end of the 19th century, classical mechanics was the most used tool
to predict the dynamic movement of material bodies, based on Maxwell’s
electromagnetism theory. But with the beginning of 20th, the theories, so far
believed to explain the physical phenomena, were challenged by Einstein’s
theory of relativity and by the new experimental techniques developed at a
microscopic level [22].
With the failure of classical physics to explain some phenomena such as
black-body radiation, atomic stability and atomic spectroscopy, a first break-
through came with the discovery of Max Planck introducing the concept of
the quantum of energy, triggering an increase in the discoveries and a all
new way of thinking. Based on Planck’s quantum concept discovery, Ein-
stein was able to introduce the photon concept and explain the photoelectric
problem. Bohr, after the discoveries of Rutherford (atomic nucleus), Planck
(quantum concept) and Einstein (photons), introduced the hydrogen atom
model where emission or absorption of radiation by atoms occurs in tran-
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sitions at various discrete energy states. Them Compton in 1923 gave the
conclusive confirmation of the corpuscular nature of light by scattering X-
rays with electrons [23].
These researchers postulates and ideas were in agreement with experimental
results but lack in the basis of a consistent theory, led Heisenberg and
Schro¨dinger to the search for the theoretical foundation underlying the ideas
developed in the last 25 years and to the principles of nowadays old quantum
mechanics (QM).
The main objective of QM is to determine the spatial positions of all
the nucleus and electrons of the system in study. The electrons of the
molecules are allowed to move in the field of a fixed nuclei, applying the
Born-Oppenheimer approximation, until they reach a self-consisting field
(SCF) [24]. At this moment the attractive and repulsive forces of all the
electrons in the system and the fixed nuclei are in a stationary state. The
nuclei are moved, after each movement SCF calculations are made until the
energy of all system can’t drop more. To this energy we call, energy min-
imization or geometry optimization and allowing to determine structural
and electronic features of all the molecules in the system [25].
Molecular Mechanics (MM) is simpler and faster than QM since it is based
on a potential energy function. It can be used with larger molecules and
evaluate the assembly and interaction of multiple molecules such as CyDs
[25].
Docking small molecules (guests or ligands) with macromolecules (hosts or
receptors) was a pioneer method during the beginning of the 1980s decade
and remains a highly field of research [26]. The molecular docking process
tries to predict the structure of the intermolecular complex that is formed
between the host and guest molecules. It allows to know the posing1 of the
ligand and be useful primarily as a hit-identification tool [27].
1process to determine if the conformation and orientation of the ligand fits the active
site. It may give many alternative results.
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1.5 Aim of this work
In the last decades there has been an enormous increase in the number of
studies and publications regarding CyDs. While 30 years ago 4 to 5 CyD
papers were published monthly, in the last decade that, on average, has
been the number of publications daily. A high number of these publications
were dedicated to the study of CyDs inclusion phenomena to be applied in
the pharmaceutical sciences field [13].
The main goal of this study consists in determining the binding modes of
the adducts formed between three natural cyclodextrins, α-, β- and γ-CyD
and two derivatives, Me- and Hp-β-CyD, with five anti-asthmatic drugs;
salbutamol, the most used short acting β-2 agonist in the treatment of
asthma, and four inhaled corticosteroids, a type of drugs applied in the
cases with more severe clinical persistence. In this thesis, we investigate
the relative stabilities at the quantum level of these adducts and validate
our approach with the available data.
Chapter 2
Theory and Methods
2.1 Quantum Mechanics
2.1.1 Schro¨dinger equation
The Schro¨dinger formulation (Equation 2.1) describes the dynamics of
microscopic matter, without time-dependent interactions which happens in
the stationary state [28].
Hψ = Eψ (2.1)
where E is the energy, ψ is the wave function which characterises the particle
movement and H the Hamiltonian operator represented by,
H = − h¯
2
2m
∇2 + V (2.2)
the h¯ is the Planck constant divided by 2pi, m describes the mass of the
electron and ∇2 called del-squared is a differential operator that represents
the partial derivative in three-dimensional cartesian coordinate systems.
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The Schro¨dinger equation cannot be solved for all systems. First of all, it
cannot be applied to atoms with more than one electron, so the solutions
for polyelectronic atoms or molecules will only be approximated to the real
value. This may be due to the different functional forms that the wave
function may adopt; another issue to take into account in this multi-electron
species is the electron spin, which can have values of +1
2
and -1
2
at the spin
angular momentum [28].
2.1.2 Hartree-Fock method
The Hartree-Fock (HF), also known as SCF method, is an approximate
method for the determination of the wave function and energy of a quantum
many-body system in the stationary state. It was one of the first methods
used in the quantum mechanics and the starting point of the post-Hartree-
Fock methods and density functional theory (DFT) [29].
Nowadays, HF is outdated and presents several limitations. Nevertheless,
it was an important milestone for the so called post-Hartree-Fock methods
that came after.
2.1.3 Density functional theory
DFT using functionals of electron density introduces a different approach.
Instead of calculating the wave function of the electrons, as done in previous
methods, it calculates the electronic energy and overall density distribution.
DFT is based on the Hohenberg-Kohn models involving a self-consistent
approach [30]. With the DFT methodology it is necessary to make an ap-
proximation due to the exchange-correlation functional, and the treatment
of these properties is strongly related with the success of this approach.
Like what happened before, with Planck and others researchers, this method,
despite the agreement with experimental results, didn’t have a consistent
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theory basis compared with the HF method and its post-methods. This led
to the development, in the 90s, of the so-called hybrid methods.
2.1.4 Hybrid methods
The hybrid methods are combinations of the exchange term of HF methods
with the correlation component of DFT methodology. Thanks to Becke and
his discoveries in this field, in the last decades the number of hybrid methods
have been increasing significantly [31]. One of the most popular exchange-
correlation functional is the Becke three-parameter exchange functional [32]
and the correlation functional Lee, Yang and Parr [33] (B3LYP), that with
an high accuracy, turn it into a very popular method. The functional used
in this work is a hybrid one, called PBE1PBE or PBE0. It is a functional
that uses 25% exchange and 75% correlation weighting [34] and was derived
from the pure functional of Perdew, Burke and Ernzerhof [35, 36].
EACM0xc = E
GGA
xc +
1
4
(EHFx + E
GGA
x ) (2.3)
It is a functional well implemented in theoretical studies and has already
been used in studies with cyclodextrins [37].
2.1.5 Basis set
A basis set in computational chemistry, is a set of basis functions of the
atomic orbitals of atoms within a molecule. This theory can be interpreted
as restricting the region of space populated by a specific electron.
In the beginning, the Slater-type orbitals were used to describe the molecu-
lar orbitals on the basis of linear combinations of atomic orbitals, but unfor-
tunately they were computationally difficult to implement, which prompted
and so the Gaussian-type orbitals to be developed. Nowadays, there are
hundreds of basis set composed by Gaussian functions [38].
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A very commonly used basis set is 6-31G. The letter G stands for Gaussian,
the number on the left of the hyphen represents the number of primitive
Gaussian functions, in this case there were 6, the numbers on the right of
the hyphen indicate the number of valence functions. In this case, we have
two numbers, so we have a double zeta basis set. The number on the left
of the letter G always represent the split 1s orbital of the hydrogen atoms
[28, 38].
It is also possible to add polarization to this basis sets, allowing the orbitals
to change shape. With this, we could have a 6-31G(d) or 6-31G* basis
set, which means that d functions were added to the non-hydrogen atoms
(heavy atoms). The hydrogen atoms can be polarized too, for instance
in the basis set 6-31G(d,p) or 6-31G**, where p functions are added to
hydrogen atoms. So, the information inside the parenthesis on the left of
the comma, is related to the heavy atoms of the system, while the one on
the right regards the hydrogen atoms. In a more complex analysis of a basis
set, like 6-31G(2df,2pd), two d functions and one f function were added to
the heavy atoms, while two p functions and one d are added to hydrogen
atoms [23].
Besides polarization, it is also possible to add diffusion to basis sets, espe-
cially when dealing with anions and molecules containing lone pairs. These
functions allow orbitals to occupy a larger region of space. To use this
function on a basis, add a single plus sign right after the G letter, like in
6-31G+(d,p), meaning that the heavy atoms have an extra one s and one p
function and when we have two plus signs, not only the heavy atoms have
extra functions, but also the hydrogen atoms will have an s diffuse function,
as in this example 6-31G++(d,p) [23].
2.1.6 Structure Optimization Details
The three dimensional structures of α-, β- and γ-cyclodextrin were obtained
in [39] while the structures of the anti-asthmatic drugs came from [40–44].
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The derivatives of the β-CyD were produced adding the necessary groups
with PyMOL [45].
Before the QM optimization calculations, the structures energy were mini-
mized in the Avogadro software [46] with the steepest descent method and
with the MMFF94 force field [47].
The geometry optimization calculations were done using the Gaussian 09
software package [48] with the PBE1PBE functional [34, 35] and the ba-
sis set 6-31G(d,p) [38] for all atoms. The calculations were performed in
vacuum with charge equal to zero and multiplicity equal to 1.
Frequency calculations were performed to make sure that the optimized
geometries were minima.
All structures were analysed and processed with Chemcraft [49] and Py-
MOL [45].
2.2 Molecular Mechanics and Molecular
Docking
Molecular mechanics is a nonquantum method, based on an empirical force
field, and consists in seeing a molecule as a gathering of particles held
together by the elastic forces. Forces that are defined in terms of a potential
energy function of internal coordinates such bond lengths, angles and torsion
angles, for instance. Diverging from QM, where the electrons are explicitly
treated in this method they are implicitly treated.
Within the MM framework, Molecular Docking, is the most commonly used
method to determine the best binding sites with as many degrees of freedom
as possible and with a realistic evaluation of energy. This method allows
the exploration of a large area of the conformational space of the system in
study, but requires the use of simple energetic models (the scoring function)
to keep computational issues limited [50].
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2.2.1 Theory
Docking protocols are a combination of search algorithms, exploring all the
degrees of freedom of the guest-host system and scoring functions allowing
the system to be sampled efficiently, ensuring the detection of the most
important binding modes [26, 27].
The first algorithms only considered translation and rotation, and treated
the ligand and receptor as rigid structures. With the computational evolu-
tion and new algorithms, nowadays is possible to treat the ligand with full
flexibility and the host as a rigid (or partially flexible) structure [51].
2.2.2 The scoring function
Docking usually uses a scoring function based on the approximation of the
standard chemical potentials of the system, with Coulomb energies and 6-12
van der Waals interactions that need to be empirically weighted. AutoDock
Vina, a new program for molecular docking and virtual screening, has a
general form for the conformation dependency in the scoring function,
c =
∑
i<j
ftitj(rij) (2.4)
where the summation is for all the pairs of atoms that can move relatively
to each other, excluding 1-4 interactions that are atoms separated by three
covalent bonds, consecutively. To each atom i is attributed a type ti, and
a symmetric group of interaction functions fti tj considering an interatomic
distance, rij.
This value can be obtained by the intermolecular and intramolecular con-
tributions:
c = cinter + cintra (2.5)
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The scoring function of Autodock Vina was inspired by X-score [52]. The
interaction functions fti tj are defined taking into account the surface dis-
tance, dij:
dij = rij −Rti −Rtj (2.6)
where Rt represents the van der Waals radius of atom type t.
ftitj(rij) ≡ htitj(dij) (2.7)
In this scoring function, hti tj is the weighted sum of steric interactions, hy-
drophobic interactions between the hydrophobic atoms and hydrogen bonds,
when applied. [53].
2.2.3 Molecular Docking Details
For the molecular docking calculations, it was necessary to prepare the
initial files and define the running parameters. First, after the initial geom-
etry optimization and assurance of working with minima energy structures,
CyDs structures where converted to a PDBQT (Protein Data Bank, par-
tial charge (Q), atom type (T)) file, and all the non-polar atoms where
eliminated. The same procedure was applied to the anti-asthmatic drugs,
followed by the introduction of flexibility in the covalent bonds. This was
done with AutodockTools Version 1.5.6 [54].
The docking grids were placed centered on the CyDs hosts and were large
enough to allow the exploration of docking solutions on both top and bot-
tom regions of the CyDs. For each system, 50 docking calculations were
done providing approximately 20 solutions each, resulting in a total of 1000
docking solutions.
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2.3 Structure Permutation and Clustering
The large quantity of docking solutions needed to be grouped in order to
identify the preferred binding modes between drugs and CyDs. A problem
in these adduct structures is that there is too much artificial variety in the
ligand distribution due to symmetry of the CyDs. These host molecules are
constituted by several sugar subunits repeats and, therefore, it is possible to
obtain the exact same binding mode in different space regions, because the
docking software is not able to deal with this symmetry issue. We solved this
problem by applying a permutation procedure where the system is rotated
periodically one unit at the time. The different root mean square deviation
(RMSD) values obtained against a reference structure were evaluated and
the smallest value was chosen as it corresponds to the structure closest to the
studied space segment. Figure 2.1a shows how two very similar docking
solutions can appear quite different before the permutation procedure.
(a) before permutation (b) after permutation
Figure 2.1: Structures of two conformations of BEC with γ-CyD
before (a) and after (b) permutations.
The permuted docking solutions were then separated in their different bind-
ing poses using a clustering procedure. The g cluster tool from the GRO-
MACS software package [55] was used with the Jarvis-Patrick method and
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a dissimilarity RMSD cutoff of 0.1 A˚. Figure 2.2 shows several clusters of
BEC docked into γ-CyD, sorted by their abundance. The images illustrate
the homogeneity within the clusters and the dissimilarity between them.
Due to our computational limitations, we had to choose the most repre-
sentative binding modes to be used in the QM optimization procedures.
In the selected conformational clusters, we chose the most representative
structures for further studies.
(a) cluster 01 (b) cluster 02
Figure 2.2: The clusters obtained from the molecular docking
calculations between γ-CyD and BDP. The clusters were sorted by
their abundance. (cont.)
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(c) cluster 03 (d) cluster 04
(e) cluster 05 (f) cluster 06
Figure 2.2: The clusters obtained from the molecular docking
calculations between γ-CyD and BDP. The clusters were sorted by
their abundance. (cont.)
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(g) cluster 07 (h) cluster 08
(i) cluster 09 (j) cluster 10
Figure 2.2: The clusters obtained from the molecular docking
calculations between γ-CyD and BDP. The clusters were sorted by
their abundance.
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2.4 Analyses
RMSD is a measurement tool used to evaluate the similarity between two
structures. Before the calculation is done, the structures are fitted to each
other by rotation and translation, taking into account that one is the ref-
erence structure. There are important criteria in the choice of reference
structures and the atoms used in the calculations to avoid unwanted results
[56]. The RMSD can be calculated with the Equation 2.8.
RMSD =
√√√√ 1
M
N∑
i=1
mid2i (2.8)
where M represents the weight of all atoms taken into account in the cal-
culation, mi is the weight of that specific atom and di is the distance in the
two structures considered for the RMSD calculation.
All binding energies were calculated according to:
∆Ebinding = Eadduct − (Ehost + Eguest) (2.9)
The enthalpic and Gibbs energies followed the same procedure using the
enthalpic and Gibbs energies from the Gaussian output.
All images were rendered using the PyMOL software [45].
Chapter 3
Results and Discussion
3.1 Optimized initial structures
3.1.1 Host molecules
In Figure 3.1 are presented the optimized structures of the CyDs used in
this study.
With more subunits available in the structure there is an expected increase
in the size of the hosts’ cavity. The methyl group presented in the β-CyD
derivative may ensure hydrophobicity, while the 2-hydroxypropyl seems to
block the lower region of the host (Figure 3.1).
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(a) α-CyD
(b) β-CyD
(c) Me-β-CyD
Figure 3.1: Optimized structure of the host molecules. On the left
column are the upper view structures and on the right the side view (cont.).
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(d) Hp-β-CyD
(e) γ-CyD
Figure 3.1: Optimized structure of the host molecules. On the left
column are the upper view structures and on the right the side view.
3.1.2 Guest molecules
The anti-asthmatic drugs (guest molecules) were also geometry optimized
(Figure 3.2).
Four of the five drugs presented have as a core, the corticosteroid group, with
the side groups substituted by esther groups (Figure 3.2a), hydroxyl and
aliphatic groups (Figure 3.2b), cyclic aliphatic and esther groups (Figure
3.2c) and halogen end atoms (Figure 3.2d). These groups will allow
the drugs to interact with the hosts quite differently. The 5th guest is
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salbutamol, a cyclic aromatic compound with a high polar side and another
more hydrophobic (Figure 3.2e). SAL is noticeable smaller than the other
four drugs and this factor, together with its amphiphilic character, can
mediate the interactions with the host molecules.
(a) Beclomethasone dipropi-
onate (BDP)
(b) Budesonide (BUD) (c) Ciclesonide (CIC)
(d) Fluticasone propionate
(FP)
(e) Salbutamol (SAL)
Figure 3.2: Optimized structures of the anti-asthmatic drugs.
3.2 Adduct structures
3.2.1 Exploring the best binding modes
Several binding modes were obtained from the molecular docking procedure
(see section 2.2.3). For each cluster of configurations, we only present the
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adduct with lowest energy. The criteria to chose which binding modes were
presented and studied further, and which were discarded, was based on both
the cluster size (population analysis) and their docking energies. All cho-
sen structures representing the binding modes were structurally optimized
at the QM level. Due to the large amount of data generated (too many
structures), we only presented the optimized structures of the adducts that
change significantly from the molecular docking to the QM calculations.
3.2.1.1 α-cyclodextrin
The molecular docking studies of BDP on α-CyD show two binding modes
of interest. In the first case, we have a propionate group inside the cavity
(Figure 3.3a), while in the other one, the aromatic ring is internalized
(Figure 3.3b).
(a) binding mode 1 (b) binding mode 2
Figure 3.3: Binding modes between α-CyD and BDP from molec-
ular docking calculations.
After the QM calculations, there was no significant difference in binding
mode 1, which tell us that this conformation, from molecular docking, was
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close the optimized one. In binding mode 2, it was possible to see a dis-
placement of the guest molecule to the outside and an accommodation in the
outer layer leading to interactions between the secondary hydroxyl groups
of the CyD and the carbonyl groups of the drug (Figure 3.4). This result
indicates that binding mode 2 was not a real minimum.
Figure 3.4: Optimized structure of binding mode 2 between α-
CyD and BDP after QM calculations.
In the case of the interaction between BUD and α-CyD, there is no clear
insertion of the drug in the cavity, and two binding modes were selected,
each one with a different side group in the hydrophobic area of the CyD
(Figure 3.5).
The QM calculation did not change these binding modes, which confirmed
the fact that this host is too small for BUD drug.
A similar result was obtained with CIC (Figure 3.6), where the drug is
only able to insert smaller side groups in the α-CyD cavity.
The QM calculations revealed that, in binding mode 2, and due to the small
size of the α-CyD cavity, the cyclic group is slightly displaced outside the
CyD, not as much as what was seen in binding mode 2 of BDP, but enough
to observe a bending behavior of the aromatic ring in one side of the adduct,
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(a) binding mode 1 (b) binding mode 2
Figure 3.5: Binding modes between α-CyD and BUD from molec-
ular docking calculations.
(a) binding mode 1 (b) binding mode 2
Figure 3.6: Binding modes between α-CyD and CIC from molec-
ular docking calculations.
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an approximation of the carbonyl of the esther group and the oxygen in the
ring to the secondary hydroxyl groups of the host (Figure 3.7).
Figure 3.7: Optimized structure of binding mode 2 between α-
CyD and CIC after QM calculations.
FP was the last corticosteroid drug studied in an adduct with α-CyD. In
this case, three promising binding modes were selected from the molecular
docking calculations (Figure 3.8). This drug displaced a variety of binding
modes when complexing with the α-CyD. In the first binding mode, the
drug in a vertical position from the carbonyl group of the cyclic part until
the fluor atom, with most of the molecule outside of the cavity and the
esther group near the upper side of the host (Figure 3.8a). In another
conformation, the same structure that was upright is now parallel covering
the upper surface while the esther group is inside the cavity (Figure 3.8b),
and in a last geometry, we observe a significant part of the molecule inside
the cavity with the side groups near the CyD hydroxyl groups (Figure
3.8c).
The QM calculations had significative impact on the binding modes that
showed a partial insertion of the linear group with an ending fluor atom and
the corticosteroid group on α-CyD (binding modes 1 and 3). In the first
binding mode, a structural relaxation leads the carbonyl group of the esther
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(a) binding mode 1 (b) binding mode 2 (c) binding mode 3
Figure 3.8: Binding modes between α-CyD and FP from molecu-
lar docking calculations.
and the hydroxyl of the corticosteroid group to approach the secondary
hydroxyl groups of the upper layer, while the distribution inside the cavity
is not affected (Figure 3.9a). In binding mode 3, the aromatic ring inside
the CyD gets expelled from the cavity leading the carbonyl group of the
esther to approach the hydroxyl groups of the layer (Figure 3.9b).
(a) binding mode 1 (b) binding mode 3
Figure 3.9: Optimized structures of binding mode 1 and 3 between
α-CyD and FP after QM calculations.
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The non-corticosteroid SAL drug, due to its smaller size and functional
groups, was able to interact with α-CyD through inclusion and non-inclusion
adducts (Figure 3.10). In binding mode 1, we observe a complete inclu-
sion of the drug, with the primary and secondary hydroxyl groups facing
the upper side of the CyD (Figure 3.10a). The binding mode 2 is a
non-inclusion adduct, with only one hydroxyl group inserted in the cavity
(Figure 3.10b).
(a) binding mode 1 (b) binding mode 2
Figure 3.10: Binding modes between α-CyD and SAL from molec-
ular docking calculations.
The QM optimization confirmed that binding mode 1 with the complete
insertion was stable and corresponded to a minimum. However, in binding
mode 2, it was observed a rearrangement of the hydroxyl groups of the guest,
favoring both inter- and intramolecular hydrogen bonds (Figure 3.11).
In conclusion, α-CyD does not seem a good host to form inclusion adducts
with the larger corticosteroid drug molecules. As a consequence, it probably
forms less stable adducts too dependent on specific interactions with its
secondary hydroxyl groups.
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Figure 3.11: Optimized structure of binding mode 2 between α-
CyD and SAL after QM calculations.
3.2.1.2 β-cyclodextrin
In β-CyD there is one extra subunit available in the structure, what in-
creases its cavity diameter (hydrophobic area). The interaction of this CyD
with the BDP drug resulted in three preferential binding modes, two of
them with inclusion type adducts (Figure 3.12).
(a) binding mode 1 (b) binding mode 2 (c) binding mode 3
Figure 3.12: Binding modes between β-CyD and BDP from molec-
ular docking calculations.
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After geometry optimization with QM calculations, the adduct structures
proved to be stable minima with only some local relaxation observed. These
binding modes with full insertion indicate that cavity size is no longer a
limitation and that the stability of the adduct will come most probably
from the complementarity between drug and CyD.
With the BUD drug, also three binding modes where obtained (Figure
3.13). The first two are inclusion adducts with the main functional group
of the corticosteroid inside the cavity, differing only in the fact that they
are inverted (Figures 3.13a and 3.13b), while binding mode 3 is a non-
inclusion complex with the guest spanned horizontally across the upper
region of the CyD (Figure 3.13c).
(a) binding mode 1 (b) binding mode 2 (c) binding mode 3
Figure 3.13: Binding modes between β-CyD and BUD from
molecular docking calculations.
In the QM calculations, the first binding mode undergoes a significant re-
organization even though the drug remains completely inserted. The main
carbonyl group approaches the secondary hydroxyl groups of β-CyD and
this bending effect leads to other interactions between the primary hydroxyl
groups of guest and host (Figure 3.14). This was observed between the
carbonyl end of the corticosteroid and the secondary hydroxyl group side
(and not with the primary), probably because in this case there are two
acceptors available per subunit, instead of one.
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(a) binding mode 1
Figure 3.14: Optimized structure of binding mode 1 between β-
CyD and BUD after QM calculations.
The two binding modes obtained with CIC showed the corticosteroid molecule
interacting with CyD’s cavity even though a complete insertion was not ob-
served (Figure 3.15). The QM calculations confirmed these binding modes
and also confirmed that a larger insertion is still limited by the cavity size
of this CyD.
The docking calculations with FP resulted in three different binding modes
(Figure 3.16). In the first case, we have an inclusion adduct with the
carbonyl of the functional group facing the top side of the CyD as can be
seen in Figure 3.16a. In the other two cases the guest is in an inverted
position with different levels of insertion. The binding mode 2 is a perfect
example of the guest in full inclusion (Figure 3.16b). However, in binding
mode 3, we have a lower level of insertion, with the aromatic ring of the
corticosteroid remaining in the internal hydrophobic region of β-CyD, while
the other groups are interacting with the secondary hydroxyl groups of the
host (Figure 3.16c).
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(a) binding mode 1 (b) binding mode 2
Figure 3.15: Binding modes between β-CyD and CIC from molec-
ular docking calculations.
(a) binding mode 1 (b) binding mode 2 (c) binding mode 3
Figure 3.16: Binding modes between β-CyD and FP from molec-
ular docking calculations.
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The QM calculations led to significant changes to binding mode 1 and 3,
favoring interactions between the hydroxyl groups. Figure 3.17a shows
the newly formed hydrogen bonds between the carbonyl group in FP and
the secondary hydroxyl layer of CyD, and between an hydroxyl group of
the corticosteroid group and the primary hydroxyl group in the other layer
of the CyD. Figure 3.17b shows a large displacement of the guest to the
outside, favoring the formation of the hydrogen bond interactions at the
top side of CyD, but also showing that the partial insertion present in this
binding mode was not stable enough.
(a) binding mode 1 (b) binding mode 3
Figure 3.17: Optimized structures of binding mode 1 and 3 be-
tween β-CyD and FP after QM calculations.
The smaller SAL drug does not have much steric hindrance when interacting
with β-CyD. In fact, the two main binding modes present two full insertions
of the drug only varying its orientation (upside down) regarding the top face
of the CyD (Figure 3.18).
The QM calculations revealed significant rearrangements in both binding
modes. Binding mode 1, in the wider side of the host, undergoes a rear-
rangement leading to a network of hydrogen bonding between two hydroxyl
groups of the host and the primary and secondary hydroxyl groups of SAL
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(a) binding mode 1 (b) binding mode 2
Figure 3.18: Binding modes between β-CyD and SAL from molec-
ular docking calculations.
(Figure 3.19a). In binding mode 2, we observe that the intramolecular
hydrogen bond network of the host reshuﬄes to introduce the secondary
hydroxyl group of SAL and allowing also the primary group to work as an
hydrogen bond donor (Figure 3.19b).
(a) binding mode 1 (b) binding mode 2
Figure 3.19: Optimized structures of binding mode 1 and 2 be-
tween β-CyD and SAL after QM calculations.
In general, β-CyD gives rise to a larger variety of binding modes and an
higher level of inclusion of guest molecules comparing with α-CyD.
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3.2.1.3 Methyl-β-cyclodextrin
Figure 3.20 presents the adducts formed between the Me-β-CyD and the
BDP drug. The first binding mode has the carbonyl end of the corticosteroid
group directed to the narrow part of the host while the propionate groups
are in the wider top part in a good degree of inclusion (Figure 3.20a). This
binding mode presents large similarities with the 1th binding mode between
BDP and β-CyD (Figure 3.12a). The binding mode 2, has the propionate
groups inside the CyDs’ cavity while the corticosteroid group is outside of
the wider part of the host (Figure 3.20b). This binding mode is also
quite similar to the the third binding mode of this drug and β-CyD. These
similarities suggest that the extra methyl group does not affect significantly
the binding of BDP. After QM calculations, both structures maintained
their configurations without major changes.
(a) binding mode 1 (b) binding mode 2
Figure 3.20: Binding modes between Me-β-CyD and BDP from
molecular docking calculations.
In the study with BUD three binding modes were identified with molecular
docking (Figure 3.21). The first binding mode is a insertion with the
carbonyl end in the narrow side of the host and the aliphatic and hydroxyl
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groups in the wider side (Figure 3.21a). In the second and third binding
modes, we have either the hydroxyl group (Figure 3.21b) or this and the
aliphatic group (Figure 3.21c), inside the cavity with the remaining groups
oriented near the methyl and secondary hydroxyl groups of the CyD. Just
like previous QM optimizations with this CyD, there were no significant
changes after these calculations.
(a) binding mode 1 (b) binding mode 2 (c) binding mode 3
Figure 3.21: Binding modes between Me-β-CyD and BUD from
molecular docking calculations.
In the study of the pro-drug CIC with Me-β-CyD, we also obtained three
different binding modes (Figure 3.22). These modes are characterized by
individual insertions of the three groups composing the drug molecule while
the remaining ones stay in the wider region of the host. In the first case we
have the propionate group inside the cavity (Figure 3.22a), in the second is
the aliphatic cyclic group (Figure 3.22b) and in the last, the corticosteroid
group inserts in the cavity (Figure 3.22c). From these adducts, the last
one was shown not to be very stable, as its configuration was significantly
changed after QM optimization (Figure 3.23). The corticosteroid group
inside the host was displaced to the wider side of the CyD, resulting in an
adduct almost with any insertion.
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(a) binding mode 1 (b) binding mode 2 (c) binding mode 3
Figure 3.22: Binding modes between Me-β-CyD and CIC from
molecular docking calculations.
Figure 3.23: Optimized structure of binding mode 3 between Me-
β-CyD and CIC after QM calculations.
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The last corticosteroid drug studied was FP, where we identified four bind-
ing modes with Me-β-CyD (Figure 3.24). The first two binding modes
are opposite to each other where the carbonyl end of the corticosteroid is in
the wider and the remaining groups arranged in the narrow side (Figure
3.24a), and vice-versa (Figure 3.24b). The third binding mode is simi-
lar to the second but without such a good degree of encapsulation of the
guest (Figure 3.24c). In the last binding mode, the terminal fluor atom
is located in the hydrophobic area of the CyD with the other two groups
in the methyl and hydroxyl groups side (Figure 3.24d). QM calculations
confirmed that binding modes 1, 2 and 4 were stable. However, binding
mode 3 changed significantly with the displacement of the aromatic ring
from the cavity and arrangement the remaining groups in the wider side,
allowing the only hydroxyl group of the guest to hydrogen bond with the
secondary hydroxyl group of the host (Figure 3.25).
With SAL interacting with Me-β-CyD, two binding modes were identified.
In both binding modes the drug is completely encapsulated in the host, one
with the hydroxyl groups of the ring pointing to the wider side, while the
methyl group is in the narrow side of the CyD (Figure 3.26a). In the
other binding mode these interaction points are inverted (Figure 3.26b).
The QM optimization revealed a series of structural reorganizations to both
binding modes (Figure 3.27). In both cases SAL is able to form an in-
tramolecular hydrogen bond between its two hydroxyl groups. However,
while in binding mode 1, both groups interact with the host (Figure 3.27a)
in binding mode 2 only one is able to do this interaction (Figure 3.27b).
The extra methyl group in Me-β-CyD created an extra difficulty for most
drugs to interact with this host, as it decreases the ability of the host to
act as an hydrogen bond donor. The increased hydrophobicity can play a
role in the affinity towards this host but, at the moment, we only observed
a decrease in the specificity.
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(a) binding mode 1 (b) binding mode 2
(c) binding mode 3 (d) binding mode 4
Figure 3.24: Binding modes between Me-β-CyD and FP from
molecular docking calculations.
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Figure 3.25: Optimized structure of binding mode 3 between Me-
β-CyD and FP after QM calculations.
(a) binding mode 1 (b) binding mode 2
Figure 3.26: Binding modes between Me-β-CyD and SAL after
molecular docking calculations.
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(a) binding mode 1 (b) binding mode 2
Figure 3.27: Optimized structures of binding mode 1 and 2 be-
tween Me-β-CyD and SAL after QM calculations.
3.2.1.4 2-hydroxypropyl-β-cyclodextrin
The first drug studied with this derivative of β-CyD was BDP and three
binding modes were identified. One with a propionate group inside the
cavity and the remaining groups organized in the wider side of the host
(Figure 3.28b) and the other two binding modes with different levels of
insertion of the corticosteroid group. While in binding mode 1 the inclusion
of the corticosteroid group is deep, near the hydroxyl of the propyl group
of the host (Figure 3.28a), the inclusion in binding mode 3 is shallow,
remaining near the aromatic rings of the Hp-β-CyD (Figure 3.28c). It
seems that with this substitution on the primary hydroxyl groups of the
host, the hydrophobicity of the cavity goes beyond the aromatic rings of
the CyD’s subunits, reaching the region of the hydroxypropyl groups. The
QM calculations showed some changes in the arrangement of the host propyl
groups but significant changes could only be observed in binding mode 1.
In Figure 3.29, we see the final configuration of this binding mode, with a
hydrogen bond between the end carbonyl of the corticosteroid group and the
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secondary hydroxyl of the propyl group. This type of interaction is similar
to what we observed with the primary hydroxyl groups of β-CyD, but in
the case of Hp-β-CyD the guest molecule inserts much deeper allowing all
the cyclic rings to be encapsulated in the cavity.
(a) binding mode 1 (b) binding mode 2 (c) binding mode 3
Figure 3.28: Binding modes between Hp-β-CyD and BDP after
molecular docking calculations.
Figure 3.29: Optimized structure of binding mode 1 between Hp-
β-CyD and BDP after QM calculations.
We identified four binding modes between BUD and Hp-β-CyD (Figure
3.30). Binding mode 1 is fully inserted in the host, with the carbonyl end
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group near the secondary hydroxyl groups and the aliphatic and hydroxyl
end groups near the hydroxypropyl substitute in the narrow side (Figure
3.30a). In binding mode 3, we only have insertion of the aliphatic linear
group with the remaining groups arranged in the wider side (Figure 3.30c).
Binding modes 2 and 4 differ mainly on the level of insertion, with one
much more encapsulated than the other, respectively (Figures 3.30b and
3.30d). The QM calculations confirmed that these binding modes were
very close to minima configurations. Nevertheless, binding modes 2 and 3
(Figure 3.31) underwent structural rearrangements to favor the formation
of hydrogen bonds between the hydroxyl and carbonyl groups of the drug
and the secondary hydroxyl groups of Hp-β-CyD.
We identified two binding modes between CIC and Hp-β-CyD. In one case,
the aliphatic cyclic ring is inside the host’s cavity (Figure 3.32a), while
the other binding mode has the propionate group inserted (Figure 3.32b).
Both binding modes show most of the drug in a very shallow position with
only partial insertion. The QM calculations did not result in significant
changes to the docking binding modes.
We identified two binding modes between FP and Hp-β-CyD with com-
pletely opposite orientations. In Figure 3.33a we observe binding mode 1
where the guest molecule is encapsulated in the host with the carbonyl end
group near the hydroxypropyl groups of the host and the remaining groups
near the secondary hydroxyl groups in the wider side. In binding mode
2 the opposite orientations are observed with the carbonyl end group in
the wider side and the other two groups inside the cavity near the hydrox-
ypropyl groups (Figure 3.33b). The QM optimizations confirmed that
these were indeed stable structures.
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(a) binding mode 1 (b) binding mode 2
(c) binding mode 3 (d) binding mode 4
Figure 3.30: Binding modes between Hp-β-CyD and BUD after
molecular docking calculations.
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(a) binding mode 2 (b) binding mode 3
Figure 3.31: Optimized structures of binding mode 2 and 3 be-
tween Hp-β-CyD and BUD after QM calculations.
(a) binding mode 1 (b) binding mode 2
Figure 3.32: Binding modes between Hp-β-CyD and CIC after
molecular docking calculations.
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(a) binding mode 1 (b) binding mode 2
Figure 3.33: Binding modes between Hp-β-CyD and FP after
molecular docking.
The docking study between SAL and Hp-β-CyD revealed three binding
modes. The first two binding modes have the primary and secondary hy-
droxyl groups near the wider side of the host and the methyl group inside the
cavity. However, they change in the degree of insertion with binding mode 1
more encapsulated (Figure 3.34a) than binding mode 2 (Figure 3.34b).
In binding mode 3, the guest molecule is inverted, compared with the pre-
vious two binding modes, with the hydroxyl groups inside the cavity and
the methyl near the top hydroxyl groups of the host (Figure 3.34c). The
QM calculations revealed significant rearrangements, favoring the hydrogen
bond formation. In the first binding mode, the secondary hydroxyl group
in the guests’ aromatic ring makes an intramolecular hydrogen bond with
the nearby primary hydroxyl group. This group and the other secondary
hydroxyl in the molecule also underwent intermolecular hydrogen bonding
in the wider side of the host and inside the cavity, respectively (Figure
3.35a). Figure 3.35b shows in the wider side, the hydroxyl groups estab-
lishing intermolecular hydrogen bonds with the host. In the last binding
mode, which is inverted, we have an intramolecular hydrogen bond between
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the hydroxyl groups of the guest and intermolecular hydrogen bonds of the
secondary hydroxyl group inside the cavity and the hydroxypropyl group
(Figure 3.35c).
(a) binding mode 1 (b) binding mode 2 (c) binding mode 3
Figure 3.34: Binding modes between Hp-β-CyD and SAL after
molecular docking calculations.
(a) binding mode 1 (b) binding mode 2 (c) binding mode 3
Figure 3.35: Optimized structures of binding mode 1, 2 and 3
between Hp-β-CyD and SAL after QM calculations.
In conclusion, with the addition of the 2-hydroxypropyl groups to the β-
CyD, we have an increase in the hydrophobicity of the cavity while still also
increasing the possibility to create hydrogen bonds with the hydroxypropyl
group. This change allowed a higher level of insertion of the corticosteriod
guests, probably due to a better accommodation inside the cavity.
52 CHAPTER 3. RESULTS AND DISCUSSION
3.2.1.5 γ-cyclodextrin
The last host studied was γ-CyD and we identified two binding modes with
the BDP drug. In both adducts the corticosteroid group is inside the cavity,
while in the first one the carbonyl end group is near the narrow side of the
host (Figure 3.36a), in the second one their relative position is inverted
(Figure 3.36b). The QM optimizations confirmed these binding modes as
energy minima.
(a) binding mode 1 (b) binding mode 2
Figure 3.36: Binding modes between γ-CyD and BDP after molec-
ular docking calculations.
The BUD drug also showed two binding modes with γ-CyD (Figure 3.37).
Like previously, we also have two binding modes where the drug is in op-
posite configuration. In Figure 3.37a we have binding mode 1 with the
carbonyl end located in the narrow side of γ-CyD, the corticosteroid group
inside the cavity, and the other groups in the wider side. In binding mode 2,
the guest structure is upside down, the corticosteroid group remains inside
the cavity but the carbonyl end and the other groups of the molecule are
in inverted positions (Figure 3.37b).
After the QM geometry optimization, in binding mode 1, we see a rear-
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(a) binding mode 1 (b) binding mode 2
Figure 3.37: Binding modes between γ-CyD and BUD after
molecular docking calculations.
rangement of the groups in the wider side of the host, allowing an hydroxyl
group to hydrogen bonding in this region and another one, in the corti-
costeroid group, to approach the narrow side (Figure 3.38a). In binding
mode 2, we have a slight displacement of the guest from the cavity to the
wider side of the host, which was promoted by the formation of hydrogen
bonds between the carbonyl end and hydroxyl groups of the corticosteroid
on this side, and another one, on the narrow side, between two hydroxyl
groups, one of the drug and one of the γ-CyD (Figure 3.38b).
We also identified two binding modes between CIC and γ-CyD. We observed
a similar behavior: one geometry with the carbonyl end of the corticosteroid
group in the narrow side of the γ-CyD, and the remaining groups in the
wider side (Figure 3.39a); while in binding mode 2, these groups are in
the opposite locations (Figure 3.39b). The QM calculations revealed a
significant rearrangement in binding mode 2 (Figure 3.40). In this config-
uration, and similarly to what we have observed with previous drugs CIC is
displaced outside the cavity to favor the formation of new hydrogen bonds
with the host.
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(a) binding mode 1 (b) binding mode 2
Figure 3.38: Optimized structures of binding mode 1 and 2 be-
tween γ-CyD and BUD after QM calculations.
(a) binding mode 1 (b) binding mode 2
Figure 3.39: Binding modes between γ-CyD and CIC after molec-
ular docking calculations.
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Figure 3.40: Optimized structure of binding mode 2 between γ-
CyD and CIC after QM calculations.
We also identified two main binding modes between FP and γ-CyD (Figure
3.41), where the drug is in an inverted position between both adducts. In
binding mode 1, the carbonyl end group is in the wider side of the host
with the remaining groups in the narrow (Figure 3.41a). In binding mode
2 these groups are located in the wider side, with the carbonyl end in the
narrow side (Figure 3.41b). The QM calculations confirmed these binding
modes were very close to minima configurations.
Like what was observed for all drugs with γ-CyD, SAL also resulted in two
binding modes. In both binding modes, we have the drug encapsulated in
the host, with the only difference lying in the guest orientation. While in
binding mode 1 the hydroxyl groups of the aromatic ring are turned to the
wider side of the γ-CyD (Figure 3.42a), in binding mode 2 they are in-
verted and facing the narrow region (Figure 3.42b). The QM calculations
showed a significant rearrangement of the guest’s hydroxyl groups, specially
in binding mode 1 (Figure 3.43). In binding mode 1, due to the high in-
clusion of the guest, we see an interaction between the secondary hydroxyl
group in the aromatic ring of the guest and the oxygen atom that connects
the subunits in the host. Also, in the narrow side, there is an interaction
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(a) binding mode 1 (b) binding mode 2
Figure 3.41: Binding modes between γ-CyD and FP after molec-
ular docking calculations.
between the hydroxyl group of the host and the hydroxyl group of the linear
group of the guest (Figure 3.43a). In binding mode 2, with an inverted
conformation of the guest, the interaction with the oxygen atom is also
present, but in this case it is established by the hydroxyl group of the linear
group while the two hydroxyl groups of the aromatic ring are interacting
with the primary hydroxyl groups in the narrow side of the γ-CyD (Figure
3.43b).
γ-CyD has an extremely wide cavity, which may be inconvenient to ac-
commodate smaller guest molecules, like SAL, due to the free space that
remains available in the hydrophobic region. With the largest corticosteroid
molecules, γ-CyD is able to accommodate them, even though the final op-
timized structure suggest that there is no enough complementary as, quite
often, the drug slides out of the cavity in order to establish hydrogen bonds
with the host.
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(a) binding mode 1 (b) binding mode 2
Figure 3.42: Binding modes between γ-CyD and SAL after molec-
ular docking calculations.
(a) binding mode 1 (b) binding mode 2
Figure 3.43: Optimized structures of binding 1 and 2 between
γ-CyD and SAL after QM calculations.
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3.2.2 Binding modes energies
In the next table are presented the electronic, enthalpic and Gibbs energies
of binding (Table 3.1) for all adducts studied. Most of the electronic
binding energies (∆E) were already calculated except for two cases which are
still running. The enthalpic (∆H) and Gibbs (∆G) binding energies require
the calculation of the frequency values. However, in several cases, these
calculations are very expensive computationally (they can run for several
months), and are not completed at the time of this thesis submission. All
calculations were obtained using Equation 2.9 in section 2.4.
All ∆E binding energies calculated are negative, resulting in adducts more
stable than the individual parts. A more detailed view shows that, BDP
adducts are more stable with α-, Me- and Hp-β-CyD which is in excellent
qualitative agreement with the experimental data [16] in Table 1.2. In
fact, the highest stability constant measured for this drug (681.6 M−1)
was in an adduct with Hp-β-CyD and, from our calculations, the sec-
ond binding mode presented the more negative electronic binding constant
(-53.3 kcal·mol−1). The BUD drug seems to form more stable adducts with
γ- and Hp-β-CyDs, in this order (Table 3.1). This is also the prefer-
ence observed in the available experimental data (Table 1.2) [17]. Our
calculations also shows that CIC forms the most stable adducts with Hp-
β-CyD. Even though, the stability constant of this adduct is significantly
high (Table 1.2), the experimental data also showed that the best adduct
is in fact Me-β-CyD. The fact that none of the binding modes with Me-β-
CyD proved to be as stable as the one with Hp-β-CyD, tells us that the
best adduct was not correctly sampled by the molecular docking procedure,
or that there is a contribution (e.g. entropy) to the binding energy that
is not visible in the electronic energies. Something similar happened with
FP, where the experimental data shows a significantly more stable adduct
with γ-CyD compared with Hp-β-CyD (Table 1.2). Our calculations show
that indeed γ-CyD has a more negative electronic binding energy, however,
the difference is very small (less than 2 kcal·mol−1). The non-corticosteroid
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SAL is interesting because, due to its smaller size, we have all calculations
finished and this allow us to compare with the electronic, enthalpic and
Gibbs binding energies of all binding modes.
In agreement with the experimental stability constant obtained by Marques
[21], α- and γ-CyD are not good host molecules probably due to their too
small or too large cavities, respectively. The lower binding energies for β-
and Me-β-CyD are in excellent agreement with the higher Ks values mea-
sured experimentally [21]. Interestingly, our computational data indicate
that SAL would have an even higher stability constant if Hp-β-CyD would
be used as an host.
The study with SAL also allows us to compare the three types of binding
energies (∆E, ∆H and ∆G). It seems that the frequency correction needed
to obtain both the enthalpic and Gibbs binding energies, does not invert the
order of the preferred binding modes. This observation is very important
to validate the qualitative analysis that we performed using the electronic
binding energies. In fact, the ∆H binding energies are usually very similar
to the ∆E ones. The most significant changes appear in the free Gibbs
energy calculations which include an entropic correction and can have a
major impact in the final values. As an example, we observed a very large
entropic energy penalty for the adducts of SAL and γ-CyD, where the drug
has too much conformational freedom in the host’s cavity, and this resulted
in positive free Gibbs energies.
The ∆G obtained between α-CyD and BDP for both binding modes is
remarkably low. This adduct has already been identified experimentally to
be very stable [16]. These authors proposed that α-CyD can stabilise both
low molecule weight drugs or larger molecules exhibiting side groups that
are able to insert in the host’s cavity. BDP seems to fulfill all these criteria,
resulting in a strong adduct with α-CyD.
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Table 3.1: Electronic, enthalpic and Gibbs energies of binding
(kcal·mol−1) obtained for each adduct studied.
CyD Drug Binding mode ∆E ∆H ∆G
α
BDP
1 -44.5 -42.7 -26.2
2 -36.7 -35.2 -20.4
BUD
1 -25.2 -23.9 -5.5
2 -11.0 -10.0 5.3
CIC
1 -31.3 b
2 -14.0 -12.4 6.9
FP
1 -32.6 b
2 -26.5 -25.5 -10.4
3 -20.2 b
SAL
1 -15.3 -13.7 3.0
2 -18.6 -17.3 -2.4
β
BDP
1 -20.1
b
2 -21.0
3 -35.9
BUD
1 -13.1
2 -12.4
3 -26.7
CIC
1 -16.5
2 -27.8
FP
1 -29.1
2 -21.8
3 -19.6
SAL
1 -30.6 -28.9 -10.4
2 -27.6 -26.5 -9.4
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Me-β
BDP
1 -17.2
b
2 -48.9
BUD
1 a
2 -16.3
3 -15.9
CIC
1 -33.2
2 -23.6
3 -26.8
FP
1 -30.7
2 -15.7
3 -17.3
4 -31.6
SAL
1 -22.0 -20.7 -2.5
2 -23.4 -21.9 -5.6
Hp-β
BDP
1 -32.4
b
2 -53.3
3 a
BUD
1 -22.5
2 -25.4
3 -27.9
4 -31.8
CIC
1 -39.9
2 -49.0
FP
1 -28.2
2 -18.5
SAL
1 -32.0 -25.4 -7.4
2 -35.5 -33.8 -14.1
3 -31.1 -29.4 -10.3
γ
BDP
1 -37.2
b
2 -34.0
BUD
1 -33.7
2 -32.9
CIC
1 -30.5
2 -36.6
FP
1 -29.6
2 -15.7
SAL
1 -9.6 -8.0 9.0
2 -16.0 -14.8 3.4
62 CHAPTER 3. RESULTS AND DISCUSSION
a - Optimization calculations still running.
b - Frequency calculations still running.
Chapter 4
Concluding Remarks
The ability of CyDs to form inclusion complexes with guest molecules has
two key factors, size complementary and specific interactions. The first
one depends on the relative size of the CyD cavity compared to the guest
molecule. The second factor concerns the driving forces allowing the guest
to form stable adducts with the CyDs, taking in consideration that these
hosts have some hydrophobic and other more hydrophilic regions and several
hydroxyl groups that are able to act as both donor and acceptor of hydrogen
bonds. Along these lines, we observed α-CyD, due to its smaller cavity
space, is more appropriate to accommodate small molecules or even just
side groups of larger compounds. γ-CyD has a quite large cavity and,
while being able to accommodate all the drugs studied, if they are not large
enough. It is not possible to maximize the number of stabilizing interactions
and an energy penalty arises in such cases. The β-CyD seems to have the
right number of subunits, giving the best close-fit for most guest molecules
and allowing a better approximation to their wider and narrow side. The
derivatizations of this CyD, like Me- and Hp-β-CyD, fine tuned the host
properties by changing its hydrophobicity and the interaction patterns.
In overall, our computational approach was able to correctly predict quali-
tatively the best matches between the anti-asthmatic drugs and the CyDs.
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We expect that the Gibbs free energies of binding, when finished, will cor-
roborate what has been already observed. One example, is the adduct
between SAL and Hp-β-CyD, which the stability has not been studied ex-
perimentally, but we expect it to be very strong.
This remarkable predictive ability shows that our computational method
can be a powerful tool designing new and unexplored combinations of
adducts.
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